THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN GP90 DERIVED FROM GLICOPROTEIN ENVELOP OF EQUINE INFECTIOUS ANEMIA VIRUS EIAV

Abstract: The present invention describes recombinant gp90 envelop protein derived from the equine infectious anemia virus, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant protein produced through genetic engineering techniques, to be used in diagnosis, vaccination or in research.

Description: THE PROCESS FOR EXPRESSION AND PRODUCTION OF RECOMBINANT PROTEIN GP90 DERIVED FROM GLYCOPROTEIN ENVELOP OF EQUINE INFECTIOUS ANEMIA VIRUS EIAV TECHNICAL FIELD OF THE INVENTION The present invention refers to the general field of the technology of the DNA recombinant proteins, for the production of the gp90 envelope protein of Equine Infectious Anemia virus (EIAV), to be used in diagnosis, vaccination, antibody production or in research field. BACKGROUND TO THE INVENTION The equine infectious anemia (EIA) is one of the oldest diseases caused by virus, having been described for the first time in France by LIGNEE, Rec. Med. Vet, 20:30, 1843, and recognized as viral disease by VALLEE and CARRE. Acad. Sci. ,139:331-333,1904. The disease affects exclusively the members of the family Equidae presenting a worldwide distribution and consequently of great economical importance. The EIA virus (EIAV) is classified as a lentivirus of the Retroviridae family (CHARMAN et al. J. Virol. 19(2): 1073 -1076,1976), it is genetic and antigenically related to the other lentiviruses which are characterized by causing persistent infection. The EIA has played a specially important role in comparative virology and in the studies of the acquired immunodeficiency syndrome (AIDS). Besides their morphological identity, both viruses possess similarities in terms of nucleotide sequences that code for structural proteins, and they infect the same cells. These viruses present genetic and antigenic variants during persistent infections, which is associated to the immunologic evasion MONTAGNIER et al. Ann. Virol., 135:119-134, 1984, MONTELARO et al. J. Biol. Chem., 259:10539-10544,1984, RUSHLOW et al. Virology, 155:309-321 , 1986, STREICHER et al. J. Am. Med. Assoc. 256:2390-2391. 1986, STOLER et al. J. Am. Med. Assoc. 256:2360-2364,1986 and HAHN The transmission of EIAV occurs mainly by arthropods vectors (tabanideos) by inoculating the virus into the animal's blood stream when feeding themselves (mechanical transmission) justifying the high prevalence of EIA in hot areas favorable to the life cycle of of these vectors ISSEL et al. Vet.. 17:251-286, 1988. EIA can also be transmitted by the placenta and colostra of mares with high virus titers, and by needles and surgical instruments contaminated with blood COGGINS Comparative diagnosis of viral diseases, NY 4:646-658, 1981 . The disease present the acute forms, subacute, chronic and mainly inaparent or assimptomatic ISSEL & COGGINS, J. Am. Vet. Med. Assoc. 174(7):727-33, 1979, and the most prominent signs are the feverish episodes, anemia hemolϊtica, anorexia, fast weight loss and ventral edema. Considering the high prevalence of assymptomatic carriers , the non conclusive clinical diagnosis and the possibility to confuse with other diseases as the trypanosomiases, piroplasmose, leptospirose, hepatitis and endoparasitoses the laboratory diagnosis plays a decisive role in the control and prevention of EIA. The accepted way to diagnose the presence of EIA has been to detect the presence of antibodies specific for the disease in the serum of affected animals using the Coggins or agar gel diffusion test described in U.S.Pat. nro.3,929,982 and U.S.Pat. No. 3,932,601. In the Coggins test, a prepared antigen is placed alongside the serum to be tested in an agar or gel medium. If EIA antibodies are present in the test serum, they will diffuse toward the antigen forming a precipitin line in the agar medium where they eventually meet. The antigen is prepared, using spleen of infected horses COGGINS & NORCROSS Cornell. Vet. 60(2):330-5, 1970 or in culture of horse leucocytes NAKAJIMA & USHIMI Infect. Immun, 3(3):373-7, 1971. This methodology is inherently insensitive in that the EIA antigen may be contaminated with non-EIA antigens during its preparation. Antibodies against non-EIA antigens may be present in the test serum and can react Even if the prepared EIA viral antigen can be purified, the Coggins test is labor intensive and demanding of considerable expertise in interpretation of results. The Coggins test procedure is also slow to yield results, it takes twenty-four to forty-eight hours for the formation of clearly visible precipiting lines. Porter, U.S.Pat.No.4,806,467, discloses a method for detecting the EIA virus using a competitite enzyme-linked immunoabsorbent assay incorporating a purified viral antigen and a monoclonal antibody. To obtain the antigen, the EIA virus must first be cultured. The antigen is the p26 core protein of the EIA virus and is obtained through (purification of the cultured virus by a variety of means) well known in the art.. The technique of culturing a virus increases the likelihood that the assay will yield false positive results since the virus may be contaminated with other forms of protein. Additionally, the EIA virus is hard to culture, making the Porter approach difficult for large scale production. The use of a synthetic peptide in an enzyme linked (immunosorbent assay) for the detection of human immunodeficiency virus (HIV) is disclosed in Shoeman, R.L. et al, Analytical Biochemistry 161 :370-379 (1987). HIV and the EIA virus are members of the retrovirus family but have dissimilar structures and distinct amino acid sequences. The main component of these preparations is therefore a protein of the virai capsid whose molecular weight is 26 KDa, (denominated p26). This is the most abundant protein of the viral particle PAREKH et al. Virology, 107:520-525, 1980, GELDERBLON, AIDS 5:617-638, 1991 , and it is highly conserved within the variant samples of the isolated viruses HUSSAIN et al. J.Virol. 61:2956-2961 , 1987, SALINOVICH et al. J. Virol. 57:71-80, 1986. and infected horses present specific antibodies anti-p26. Darrel & Peisheng, the U.S. Patent No. 5,427,907, discloses a method to use a synthetic peptide as the antigen in an immunoassay for the detection of antibodies against the equine infectious anemia virus in the serum of horses. This procedure include only the search of some epitopes of virus proteins. It is an object of the present invention to describe the recombinant gp90 envelope protein from AIEV, their corresponding encoding recombinant DNA molecule and the process of production of the recombinant gp90 envelope protein produced through techniques of genetic engineering, to be used for diagnosis, vaccination or in research. BRIEF DESCRIPTION OF THE DRAWINGS These and other objects, features and many attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein: Figure 1 shows the vector used for the expression of the recombinant gp90 envelope protein Figure 2 shows the amino acid sequence of the recombinant gp90 envelope protein Figure 3 shows the pattern of hydrophilicity of the recombinant gp90 envelope protein Figure 4 shows a print of SDS-PAGE of expressed and purified recombinant gp90 protein in E. coli DETAILED DESCRIPTION OF THE INVENTION The methodology used for the production of the recombinant gp90 envelope protein consists of the cloning and expression, in microorganisms, of the DNA corresponding to the gene that codes the protein gp90 of the EIA using the methodology of the genetic engineering. In order to better understand this invention the following examples, for illustrative purposes only, are described. The examples illustrate the present invention and are not intended to limit it in spirit or scope. The process can be understood better through the following description in consonance with the examples. EXAMPLE 1 Virus multiplication (1) For multiplication of the virus cells from equine derme were used (ED) or other cells that allow replication of the virus AIE. EXAMPLE 2 Extraction of genomic DNA( 2) To obtain the genomic DNA (pro virus) the of cells were washed with saline STE (Tris-HCI 10-10.5 mM pH 8-8.5 , NaCI 0.1 M, EDTA 1-1.5 mM). The following stage was the lysis of the cells with a solution of STE, duodecil sodio(SDS sulfato) and proteinase K,(Sigma, USES) for 10-30 minutes, incubated for 50°C-55°C for 12-18 hours. The precipitation of the DNA was made with isopropanol and centhfuged. The pellet was homogenized in water transferred to eppendorf tube and incubated for 60°C-65°C for 1-2 hours for complete breakup of the DNA EXAMPLE 3 DNA amplification^) The amplification of the DNA (3) starting from the proviral DNA obtained in the stages 1 , 2, or starting from the vector that contains the cloned DNA of the gene GP-90 it wascarried out using as primers the following specific oligonucleotides 5'CAGTGGATCCT TCCCGGGGTGTAGA-3 and 5'CAATCTGCAGAATTAGTCCAGTGTTAG-3'. Those oligonucleotides were drawn to amplify, through polymerase chain reaction (PCR), the DNA region that encodes the corresponding fragment of the gp90 envelope protein. The primers also contains the sites for the restriction enzymes BamH-1 and Hind III. TCCCGGGGTGTAGA-3 and 5'CAATCTGCAGAATTAGTCCAGTGTTAG-3'. Those oligonucleotides were drawn to amplify, through polymerase chain reaction (PCR), the DNA region that encodes the corresponding fragment of the gp90 envelope protein. The primers also contains the sites for the restriction enzymes BamH-1 and Hind III. The PCR reaction was performed with Taq polymerase buffer (50mM KCI, 100 mM Tris-HCI pH 9.0-9.5, 1.5-2.5 mM MgCl2 and 1-2% triton X-100), 0.1-1 U of Taq polymerase (Promega .E.U.A., Cat. no. M186A), 0.5-1.5 mM MgCl2, 20-50mM of each nucleotide (dATP,dCTP,dGTP,dTTP) 10-30 μmoles of each primer, and 0.01a 0.1 μg cDNA and H2O q.s.p. 50-100 Dl. The reaction was performed in 1-2 cycles at 94-96°C/1-2 min; 53 to 55°C/1-2 min.; 70-72°C /1 - 2 min; 30 cycles at 94-96°C/1 to 2 min; 36-38°C/1-2min; 70-72°C/1-2 min and more 1 cycle to 94-96X/1-2 min; 36 -38X/1 to 2 min; 70-72°C/10-15 min. The PCR product was fractionated by electrophoresis in 1.5-2.0% agarose gel and purification was made by cutting out the band of the gel. The band was diluted in 2-3 volumes of Nal solution (Nal 8M + 0.022 M DTT) and sodium phosphate buffer (1M pH 6.0-6.5) and incubated for 5-10 min. at 50-56°C. Glass beads were added to the suspension, mixed , incubated 1-5 min. at room temperature and centrifuged 10-30 seconds . The spheres were washed with ethanol buffer(75% of ethanol, 0.01 M Tris- HCI, pH 7.0-7.6, 0.01 M EDTA, pH 8.0-8.5). The DNA was eluled from the glass spheres with buffer (Tris pH 7.0-7.4 10 mM, 1-3 mM EDTA) at 50-56° C for 1-5 min. EXAMPLE 4 Cloning (4) The PCR product was digested with enzyme Hind III with 10-20 U of Hind III (Biolabs, England) plus 3-5 μl buffer (Promega,EUA) in 30-50 μl volume of H2O . The reactions were incubated at 37°C for 2-4 h. After this time 10-20 U of Bam HI (Biolabs, England) plus 5-10 μl of react III buffer (BRL, USA) were added to a final 50-1 OOμl volume of H2O dd and it was incubated at 37°C for 2-4.h. For cloning of the PCR product into plasmid PDS-56 (Figure 1 ), the vector was digested with 10-20 U of enzyme Hind lll(Promega, USA), 2-5μl buffer I B (Promega,E.U.A.) in 20-50μl final volume of H2O , and incubation at 37°C for 2-4 h. To the reaction was added10-20 U of the enzyme Bam HI (Promega, USA), 5-10 μl of react III (BRL, E.U.A), in 50-1 OOμl final volume of H2O , and incubation at 37°C for 2-4 h. The product of this digestion was resolved in a 1% TAE-agarose gel electrophoresis. The band corresponding to the digested plasmid was cutted out of the gel, transferred to a Eppendorf tube (1 ,5 ml) and purified. In the ligation reaction 20-50 μg of the DNA fragment insert was added to 5-15 μg of the vector DNA, plus 0.5-2.0 U of T4 ligase (Promega, USA), 5mM ATP (Promega,E.U.A.), ligation buffer(Promega,E.UA), H2O dd qsp 15μl, with incubation at 14-16°C (BOD, FANEN, Brazil) for 12-18 h. EXAMPLE 5 Transformation (5) The bacterial transformation was done with Escherichia coli by adding the ligation reaction completed to 40-60μl volume buffer(Ths 10 mM pH 7.2- 7.4. EDTA 1 mM) to 100 μl of competent bacteria suspension. The tubes were slightly rotated and immediately incubated on ice bath for 20-40 min . After that, they were submitted to a thermal shock at 40-42°C for 1-3 min. and kept on ice bath for further 20-40 seconds. LB medium (Bacto triptona 1 % p/v, extract of yeast 0.5% p/v, NaCI 171 mM) without antibiotic was added at double volume and incubated at 37°C for 1-2h. The bacteria were pelleted, homogenized in LB and inoculated in Petri dish plates with LB agar (agar 1.5% p/v, yeast extract 0.5% p/v, triptone 0.1 % p/v, NaCI 0.5% p/v pH 7.2-7.5) with 50-200 μg/ml ampicillin and 20-100 μg/ml kanamycin. The plates were incubated at 37°C for 15-24 h. For the selection of the positive clones they were grown in LB with 50-200 μg/ml ampicillin and 20-100 Dg/rri kanamycin at 37°C under agitation for 15-20 h. After incubation a PCR using specific primers of the vector (for amplification of the area corresponding to insert) being the primer (sense) 5'-TTCATTAAAGAGGAGAAATT-3' and primer (anti-sense) 5'-CTATCAACAGGAGTCCAAGC-3' .The reaction was made with Taq. polymerase bufferlOX (KCI 500 mM, Tris-HCI 100 mM pH 9.0-9.5, MgCl2 15-25 mM and triton X-100 1-2%), 0.5-1.0 U of Taq polymerase (Promega, USA), 0.5-1.5 mM MgCl2, 20-50 mM of each nucleotide (dATP, dCTP, dGTP, dTTP), 10-30 pmoles of each primer, 0.5- 1 μl of bacterial suspension and H2θdd sterile qsp 20-40μl. The reaction was processed with 1 -3 cycles of 94-96°C/5min., 50-55°C/1-2 min., 70-72°C/1-2 min.; 30 cycles of 94-96°C/30-45 seg., 45-50°C/30^5 seg., 70-72°C/30-45 seg. and 1 cycle of 94-96°C/1-2 min., 45-50°C/1-2 min., 70-72°C/10-15min. The product of this reaction was fractionated through 1-2%.agarose gel electrophoresis. EXAMPLE 6 Sequencing (6) The positive clones were sequenced to confirm the sequence of Figure 2 and presents the hydrofobicity profile as showed in Figure 3. EXAMPLE 7 Protein production (7) The positive clones were used for production of protein and they were grown in LB medium with 50-200 μg/ml ampicillin, 50-200 of Kanamycin μg/ml and incubated at 37°C under agitation until the optical density (OD 600 nm) of 0.5-0.7. Then, for the induction of the protein, IPTG(lsopropyl-β-D- thiogalactpyranoside) to 0.2-0.4 M was added and incubated for 3-5 h. The

Claims: bacteria were centrifuged, the supernatant was discarded and the pellet homogenized in buffer A (guanidine-HCI 5-6 M, sodium phosphate 0.1-0.2 M, Tris 0.01 -0.02 M pH 7.8.-8.0) with agitation for 1-2 h. A polyacrylamide gel shows the expression in the bacteria. EXAMPLE 8 Protein purification (8) After the centrifugation the supernatant was applied to a column with Ni- NTA (nickel chelate) resin. For purification of the protein the column was washed sequentially with buffer A, buffer B (Urea 7-8 M, phosphate of sodium 0, 1 -0,2 M, Tris 0.01-0.02 M pH 7.8-8.0) and with buffer C (Urea 7-8 M, phosphate of sodium 0.1 -0.2 M, Tris 0.01 -0.02 M pH 7.0-7.2). The protein was eluted with buffer D (Urea 7-8 M, sodium phosphate 0.1-0.2 M, Tris 0.01 -0.02 M pH 5.0-5.2) and sequentially with Urea 7-8 M, phosphate of sodium 0.1-0.2 M, Tris 0.01 -0.02 M pH 40-4.2. Fractions were collected and 50μl of each fraction was diluted v/v in sample buffer, heated for 10 min. and submitted to electrophoresis in polyacrylamida gel (SDS-PAGE). The gel was analyzed for the presence of the fraction that just contained the band corresponding to the purified recombinant protein. (Figure 4) While the present invention has been described in connection with examples, it will be understood that modifications and variations apparent to those ordinary skill in the art are within the scope of the present invention. WHAT IS CLAIMED IS: 1 .Process for production of the recombinant gp 90 Equine Infectious Anemia envelope protein in comprising the following steps: (1 ) Virus multiplication (2) Genomic DNA extraction (3)DNA amplification (4)cloning (5) transformation (6)Sequencing (7) Protein production (8) Protein purification 2.The process according to claim 1, wherein the stages: (1), (2), (3), (4) ,(5), (6) can be optional. 3. Process production of the recombinant gp 90 EIA envelope protein according to claim 1 , wherein the amplification of DNA (3) is done using EIA or any other one with the same sequence. 4. Process for production of the recombinant recombinant gp 90 EIA envelope protein according to claim 1 , wherein the cloning (4) of the DNA is done in plasmid pDS56 or any other expression vector. 5. Process for production of the recombinant gp 90 EIA envelope protein according to claim 1 , wherein the transformation of the competent bacteria (5) is done with bacteria Escherichia coli or any other microorganism 6. Process for production of the recombinant gp 90 EIA envelope protein according to claim 1, wherein the protein production (7) is done in Escherichia coli or any other microorganism 7. Process for production of the recombinant gp90 EIA envelope protein according to claim 1 , wherein the fact that the purification of the protein (8) is done in a column of nickel chelate or any other method that allows the purification of the protein. 8. Recombinant gp 90 EIA envelope protein manufactured through the demanded process of 1-6, wherein the structure presents the following aminoacids: HisHisHisHisHisHisSerPheProGly. CysArgProPheGlnAsnTyrPheSerTyrGlu. ThrAsnArgSerMetHisMetAspAsnAsn. ThrAlaThrLeuLeuGluAlaTyrHisArg. GlulleThrPhelleTyrLysSerSerCysThr. AspSerAspHisCysGlnGluTyrGlnCys. Ly s LysVal Asn LeuAsnSerSerAspSer. SerAsnSerValArgValGluAspValThr. AsnThrAlaGluTyrTrpGlyPheLysTrp. LeuGluCysAsnGlnThrGluAsnPheLys. ThrlleLeuValProGluAsnGluMetVal. AsnlleAsnAspThrAspThrTrpllePro. LysGlyCysAsnGluThrTrpAlaArgVal. LysArgCysProlleAsplleLeuTyrGly. HeHisProlleArgLeuCysValGlnPro ProPhePheLeuValGlnGluLysGlylle. AlaAspThrSerArglleGlyAsnCysGly ProThrllePheLeuGlyValLeuGluAsp. AsnLysGlyValValArgGlyAspTyrThr AlaCysAsnValArgArgLeuAsnlleAsn. ArgLysAspTyrThrGlylleTyrGlnVal. ProllePheTyrThrCysThrPheThrAsn. lleThrSerCysAsnAsnGluProllelle SerVallleMetTyrGluThrAsnGlnVal. GInTyrLeuLeuCysAsnAsnAsnAsnSer. AsnAsnTyrAsnCysValValGlnSerPhe. GlyVallleGlyGlnAlaHisLeuGluLeu. ProArgProAsnLysArglleArgAsnGln. SerPheAsnGlnTyrAsnCysSerlleAsn. AsnLysThrGluLeuGluThrTrpLysLeu. ValLysThrSerGlyValThrProLeuPro. HeSerSerGluAlaAsnThrGlyLeu

Inventors: BIAS FORTES FERRAZ ISABELLA, CERQUEIRA LEITE ROMULO, GEESSIEN KROON ERNA, PEREGRINO FERREIRA PAULO CESAR, PIMENTA DOS REIS KARLISSON JEN, BIAS FORTES FERRAZ, ISABELLA, CERQUEIRA LEITE, ROMULO, GEESSIEN KROON, ERNA, PEREGRINO FERREIRA, PAULO, CESAR, PIMENTA DOS REIS, KARLISSON, JENNER
Applicants: BIAS FORTES FERRAZ ISABELLA, CERQUEIRA LEITE ROMULO, GEESSIEN KROON ERNA, PEREGRINO FERREIRA PAULO CESAR, PIMENTA DOS REIS KARLISSON JEN, UNIV MINAS GERAIS, BIAS FORTES FERRAZ, ISABELLA, CERQUEIRA LEITE, ROMULO, GEESSIEN KROON, ERNA, PEREGRINO FERREIRA, PAULO, CESAR, PIMENTA DOS REIS, KARLISSON, JENNER, UNIVERSIDADE FEDERAL DE MINAS GERAIS
Application year: 1997
Main classification: C12N15
IPC codes: C07K14, C12N15